Document is current
Any future updates will be listed below
-
Authors
Wickel, Jonathan https://orcid.org/0000-0002-5854-3759
Ceanga, Mihai
Vlad, Benjamin https://orcid.org/0009-0002-8830-0173
von Stackelberg, Nikolai https://orcid.org/0000-0003-4003-5809
Tochoedo, Nounagnon Romaric
Schulz, Danilo
Yomade, Olaposi
Dudziak, Diana https://orcid.org/0000-0001-9358-134X
Geis, Christian https://orcid.org/0000-0002-9859-581X
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GE2519/8-2, GE2519/9-2)
Deutsche Forschungsgemeinschaft (DU548/9-1 (515982377))
Deutsche Forschungsgemeinschaft (EXC 2051 – Project-ID 390713860)
Bundesministerium für Bildung und Forschung (01GM1908E)
Schilling Foundation
Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Jena
- License Information
-
More Information
Article History
Received: 30 October 2025
Accepted: 4 May 2026
First Online: 30 May 2026
Competing interests
: The authors declare the following competing interests: J.W. reports honoraria from Argenx, Alexion, travel support from Neuraxpharm, and research support from Ionis Pharmaceuticals. M.C. reports honoraria from Argenx. C.G. received speaker fees and compensation for advisory boards from Alexion, Roche, Sobi, Argenx, Kyowa, Astra Zeneca and travel support from Alexion. D.D. received compensation for advisory board from Johnson & Johnson and received funding from the company Affimed in an independent project. B.V., N.S., D.S., N.R.T., R.T., and O.Y. declare no competing interests.
